Skip to main content
SpringerLink
Log in

Buprenorphine: Side Effects and Tolerability

  • Chapter
  • First Online:
Handbook of Methadone Prescribing and Buprenorphine Therapy

Abstract

Opioid analgesics play an important role in the management of acute and chronic pain. As such, there has been a dramatic increase in opioid prescribing over the past two decades. There are currently many practitioners who have serious concerns with prescribing because of fear of side effects, tolerability, addiction, colleague criticism, and legal sanctions and both the efficacy and safety of the use of opioids for acute and chronic pain have recently been subjected to increasing scrutiny (J Pain Symptom Manage 20(4):293–307, 2000; J Pain Symptom Manage 11(4):203–217, 1996).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Fishman SM, Wilsey B, Yang J, Reisfield GM, Bandman TB, Borsook D. Adherence monitoring and drug surveillance in chronic opioid therapy. J Pain Symptom Manage. 2000;20(4):293–307.

    Article  PubMed  CAS  Google Scholar 

  2. Portenoy RK. Opioid therapy for chronic nonmalignant pain: a review of the critical issues. J Pain Symptom Manage. 1996;11(4):203–17.

    Article  PubMed  CAS  Google Scholar 

  3. Radbruch L, Vielvoye-Kerkmeer A. Buprenorphine TDS: the clinical development rationale and results. Int J Clin Pract Suppl. 2003;133:15–8; discussion 23–4.

    Google Scholar 

  4. Kintz P. Deaths involving buprenorphine: a compendium of French cases. Forensic Sci Int. 2001;121(1–2):65–9.

    Article  PubMed  CAS  Google Scholar 

  5. Kintz P. A new series of 13 buprenorphine-related deaths. Clin Biochem. 2002;35(7):513–6.

    Article  PubMed  CAS  Google Scholar 

  6. Tzschentke TM. Behavioral pharmacology of buprenorphine, with a focus on preclinical models of reward and addiction. Psychopharmacology (Berl). 2002;161(1):1–16.

    Article  CAS  Google Scholar 

  7. Reynaud M, Petit G, Potard D, Courty P. Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction. 1998;93(9):1385–92.

    Article  PubMed  CAS  Google Scholar 

  8. Tracqui A, Kintz P, Ludes B. Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities. J Anal Toxicol. 1998;22(6):430–4.

    Article  PubMed  CAS  Google Scholar 

  9. Gaulier JM, Marquet P, Lacassie E, Dupuy JL, Lachatre G. Fatal intoxication following self-­administration of a massive dose of buprenorphine. J Forensic Sci. 2000;45(1):226–8.

    PubMed  CAS  Google Scholar 

  10. Whistler JL. Examining the role of mu opioid receptor endocytosis in the beneficial and side-­effects of prolonged opioid use: from a symposium on new concepts in mu-opioid pharmacology. Drug Alcohol Depend. 2012;121(3):189–204.

    Article  PubMed  CAS  Google Scholar 

  11. Zaki PA, Keith Jr DE, Brine GA, Carroll FI, Evans CJ. Ligand-induced changes in surface mu-opioid receptor number: relationship to G protein activation? J Pharmacol Exp Ther. 2000;292(3):1127–34.

    PubMed  CAS  Google Scholar 

  12. Sittl R, Nuijten M, Nautrup BP. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study. Clin Ther. 2005;27(7):1022–31.

    Article  PubMed  CAS  Google Scholar 

  13. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of ­buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 1994;55(5):569–80.

    Article  PubMed  CAS  Google Scholar 

  14. Dahan A, Yassen A, Bijl H, et al. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth. 2005;94(6):825–34.

    Article  PubMed  CAS  Google Scholar 

  15. Yassen A, Olofsen E, Dahan A, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics. J Pharmacol Exp Ther. 2005;313(3):1136–49.

    Article  PubMed  CAS  Google Scholar 

  16. Zenz M, Piepenbrock S, Tryba M, Klauke W, Everlien M. [Sublingual buprenorphine tablets: initial clinical experiences in long-term therapy of cancer pain]. Fortschr Med. 1983;101(5):191–4.

    PubMed  CAS  Google Scholar 

  17. Radbruch L, Sabatowski R, Petzke F, Brunsch-Radbruch A, Grond S, Lehmann KA. Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients. Palliat Med. 2001;15(4):309–21.

    Article  PubMed  CAS  Google Scholar 

  18. Cowan A, Lewis JW, Macfarlane IR. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol. 1977;60(4):537–45.

    Article  PubMed  CAS  Google Scholar 

  19. Dahan A, Yassen A, Romberg R, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth. 2006;96(5):627–32.

    Article  PubMed  CAS  Google Scholar 

  20. Kjaer M, Henriksen H, Knudsen J. A comparative study of intramuscular buprenorphine and morphine in the treatment of chronic pain of malignant origin. Br J Clin Pharmacol. 1982;13(4):487–92.

    PubMed  CAS  Google Scholar 

  21. Pergolizzi J, Aloisi AM, Dahan A, et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract. 2010;10(5):428–50.

    Article  PubMed  Google Scholar 

  22. Campora E, Merlini L, Pace M, et al. The incidence of narcotic-induced emesis. J Pain Symptom Manage. 1991;6(7):428–30.

    Article  PubMed  CAS  Google Scholar 

  23. Noda J, Umeda S, Arai T, Harima A, Mori K. Continuous subcutaneous infusion of buprenorphine for cancer pain control. Clin J Pain. 1989;5(2):147–52.

    Article  PubMed  CAS  Google Scholar 

  24. Likar R, Kayser H, Sittl R. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials. Clin Ther. 2006;28(6):943–52.

    Article  PubMed  CAS  Google Scholar 

  25. Tantucci C, Paoletti F, Bruni B, et al. Acute respiratory effects of sublingual buprenorphine: comparison with intramuscular morphine. Int J Clin Pharmacol Ther Toxicol. 1992;30(6):202–7.

    PubMed  CAS  Google Scholar 

  26. Fudala PJ, Bridge TP. Foreword to: buprenorphine and buprenorphine/naloxone: a guide for clinicians. Drug Alcohol Depend. 2003;70(2 Suppl):S1–2.

    Article  PubMed  Google Scholar 

  27. Ling W, Charuvastra C, Collins JF, et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction. 1998;93(4):475–86.

    Article  PubMed  CAS  Google Scholar 

  28. Robbie DS. A trial of sublingual buprenorphine in cancer pain. Br J Clin Pharmacol. 1979;7 (Suppl 3):315S–7.

    Article  PubMed  Google Scholar 

  29. Przeklasa-Muszynska A, Dobrogowski J. Transdermal buprenorphine in the treatment of cancer and non-cancer pain—the results of multicenter studies in Poland. Pharmacol Rep. 2011;63(4):935–48.

    PubMed  CAS  Google Scholar 

  30. Petry NM, Bickel WK, Piasecki D, Marsch LA, Badger GJ. Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine. Am J Addict. Summer 2000;9(3):265–9.

    Article  CAS  Google Scholar 

  31. Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-­tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349(10):949–58.

    Article  PubMed  CAS  Google Scholar 

  32. Auriacombe M, Fatseas M, Franques-Reneric P, Daulouede JP, Tignol J. [Substitution therapy in drug addictions]. Rev Prat. 2003;53(12):1327–34.

    PubMed  Google Scholar 

  33. Berson A, Gervais A, Cazals D, et al. Hepatitis after intravenous buprenorphine misuse in heroin addicts. J Hepatol. 2001;34(2):346–50.

    Article  PubMed  CAS  Google Scholar 

  34. Purdue Pharmaceuticals. Butrans® (buprenorphine) transdermal system package insert. Richmond, VA; 2010.

    Google Scholar 

  35. Sittl R, Griessinger N, Likar R. Analgesic efficacy and tolerability of transdermal ­buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther. 2003;25(1):150–68.

    Article  PubMed  CAS  Google Scholar 

  36. Sorge J, Sittl R. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2004;26(11):1808–20.

    Article  PubMed  CAS  Google Scholar 

  37. Radbruch L. Buprenorphine TDS: use in daily practice, benefits for patients. Int J Clin Pract Suppl. 2003;133:19–22; discussion 23–4.

    Google Scholar 

  38. Likar R, Griessinger N, Sadjak A, Sittl R. [Transdermal buprenorphine for treatment of chronic tumor and non-tumor pain]. Wien Med Wochenschr. 2003;153(13–14):317–22.

    Article  PubMed  Google Scholar 

  39. Sacerdote P. Opioids and the immune system. Palliat Med. 2006;20(Suppl 1):s9–15.

    PubMed  Google Scholar 

  40. Meczekalski B, Podfigurna-Stopa A, Warenik-Szymankiewicz A, Genazzani AR. Functional hypothalamic amenorrhea: current view on neuroendocrine aberrations. Gynecol Endocrinol. 2008;24(1):4–11.

    Article  PubMed  CAS  Google Scholar 

  41. Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. J Pain. 2002;3(5):377–84.

    Article  PubMed  Google Scholar 

  42. Aloisi AM, Pari G, Ceccarelli I, et al. Gender-related effects of chronic non-malignant pain and opioid therapy on plasma levels of macrophage migration inhibitory factor (MIF). Pain. 2005;115(1–2):142–51.

    Article  PubMed  CAS  Google Scholar 

  43. Daniell HW. Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain. J Pain. 2008;9(1):28–36.

    Article  PubMed  CAS  Google Scholar 

  44. Ceccarelli I, De Padova AM, Fiorenzani P, Massafra C, Aloisi AM. Single opioid administration modifies gonadal steroids in both the CNS and plasma of male rats. Neuroscience. 2006;140(3):929–37.

    Article  PubMed  CAS  Google Scholar 

  45. Aurilio C, Ceccarelli I, Pota V, et al. Endocrine and behavioural effects of transdermal buprenorphine in pain-suffering women of different reproductive ages. Endocr J. 2011;58(12):1071–8.

    Article  PubMed  CAS  Google Scholar 

  46. Bliesener N, Albrecht S, Schwager A, Weckbecker K, Lichtermann D, Klingmuller D. Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence. J Clin Endocrinol Metab. 2005;90(1):203–6.

    Article  PubMed  CAS  Google Scholar 

  47. Lasseter KC, Venitz J, Eltahtawy A, et al. Systemic pharmacokinetic (PK) study of buprenorphine (B) in mild to moderate chronic hepatic impairment (CHI). Clin Pharmacol Ther. 2001;69:P2.

    Google Scholar 

  48. Tegeder I, Geisslinger G, Lotsch J. [Therapy with opioids in liver or renal failure]. Schmerz. 1999;13(3):183–95.

    Article  PubMed  CAS  Google Scholar 

  49. Deng J, St Clair M, Everett C, Reitman M, Star RA. Buprenorphine given after surgery does not alter renal ischemia/reperfusion injury. Comp Med. 2000;50(6):628–32.

    PubMed  CAS  Google Scholar 

  50. Summerfield RJ, Allen MC, Moore RA, Sear JW, McQuay HJ. Buprenorphine in end stage renal failure. Anaesthesia. 1985;40(9):914.

    Article  PubMed  CAS  Google Scholar 

  51. Bennett WM, Aronoff GR, Morrison G, et al. Drug prescribing in renal failure: dosing guidelines for adults. Am J Kidney Dis. 1983;3(3):155–93.

    PubMed  CAS  Google Scholar 

  52. Filitz J, Griessinger N, Sittl R, Likar R, Schuttler J, Koppert W. Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine. Eur J Pain. 2006;10(8):743–8.

    Article  PubMed  CAS  Google Scholar 

  53. Mercadante S, Arcuri E. Opioids and renal function. J Pain. 2004;5(1):2–19.

    Article  PubMed  CAS  Google Scholar 

  54. Griessinger N, Sittl R, Likar R. Transdermal buprenorphine in clinical practice—a post-­marketing surveillance study in 13,179 patients. Curr Med Res Opin. 2005;21(8):1147–56.

    Article  PubMed  CAS  Google Scholar 

  55. Likar R, Sittl R. Transdermal buprenorphine for treating nociceptive and neuropathic pain: four case studies. Anesth Analg. 2005;100(3):781–5, table of contents.

    Google Scholar 

  56. Hans G. Buprenorphine—a review of its role in neuropathic pain. J Opioid Manag. 2007;3(4):195–206.

    PubMed  Google Scholar 

  57. Induru RR, Davis MP. Buprenorphine for neuropathic pain--targeting hyperalgesia. Am J Hosp Palliat Care. 2009–2010;26(6):470–3.

    Google Scholar 

  58. Wolff RF, Aune D, Truyers C, et al. Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain. Curr Med Res Opin. 2012;28(5):833–45.

    Article  PubMed  CAS  Google Scholar 

  59. Tassinari D, Sartori S, Tamburini E, et al. Adverse effects of transdermal opiates treating moderate-­severe cancer pain in comparison to long-acting morphine: a meta-analysis and ­systematic review of the literature. J Palliat Med. 2008;11(3):492–501.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Anesthesiology, Dartmouth Hitchcock Medical Center, Dartmouth Medical School, One Medical Center Drive, Lebanon, NH, 03756, USA

    Tabitha Washington MD, MS & Gilbert J. Fanciullo MD, MS

Authors
  1. Tabitha Washington MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gilbert J. Fanciullo MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tabitha Washington MD, MS .

Editor information

Editors and Affiliations

  1. , Dept of Pain Med and Palliative Care, Beth Israel Medical Center, Union Square East 10, New York, 10003, New York, USA

    Ricardo A. Cruciani

  2. , Dept of Pain Mgmt and Palliative Care, Beth Israel Medical Center, East 17th Street 350, New York, 10003, New York, USA

    Helena Knotkova

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Washington, T., Fanciullo, G.J. (2013). Buprenorphine: Side Effects and Tolerability. In: Cruciani, R., Knotkova, H. (eds) Handbook of Methadone Prescribing and Buprenorphine Therapy. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6974-2_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-6974-2_14

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-6973-5

  • Online ISBN: 978-1-4614-6974-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation